ArticleBioconjugate chemistry2011
89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging.
Article in Bioconjugate chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 128 citations in OpenAlex.
- First-in-Human Study of the Carbohydrate NanoparticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- In Vivo Immunoscoring Technique to Monitor Anti-CD47 Immunotherapy Efficacy in Triple-Negative Breast Cancer.Cancer medicine · 2026Article
- Cell Selective STING-Activating Polysaccharide Immunomodulators for Cancer Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- The Emergence of Nanotechnology in the Prognosis and Treatment of Myocardial Infarctions.Recent patents on nanotechnology · 2025Review
- Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.Bioactive materials · 2024Review
- Cross-Modal Imaging Reveals Nanoparticle Uptake Dynamics in Hematopoietic Bone Marrow during Inflammation.ACS nano · 2024Article
- Host-functionalization of macrin nanoparticles to enable drug loading and control tumor-associated macrophage phenotype.Frontiers in immunology · 2024Article
- Tumor-Associated Macrophage Targeting of Nanomedicines in Cancer Therapy.Pharmaceutics · 2023Review
- Functional Diversity in Radiolabeled Nanoceramics and Related Biomaterials for the Multimodal Imaging of Tumors.ACS bio & med chem Au · 2023Review
- Radiolabeled Liposomes for Nuclear Imaging Probes.Molecules (Basel, Switzerland) · 2023Review
- Biodegradable Biopolymeric Nanoparticles for Biomedical Applications-Challenges and Future Outlook.Materials (Basel, Switzerland) · 2023Review
- Bioimaging Probes Based on Magneto-Fluorescent Nanoparticles.Pharmaceutics · 2023Review
- Nanotheranostic Strategies for Cancer Immunotherapy.Small methods · 2022Review
- Cell sorting microbeads as novel contrast agent for magnetic resonance imaging.Scientific reports · 2022Article
- Evaluation of differentScientific reports · 2022Article
- Current Development of Nano-Drug Delivery to Target Macrophages.Biomedicines · 2022Review
- Polymeric nanoparticles in the diagnosis and treatment of myocardial infarction: Challenges and future prospects.Materials today. Bio · 2022Review
- In Vivo PET Imaging of Monocytes Labeled with [Cancers · 2021Article
- Characterization of Intrinsically Radiolabeled Poly(lactic-Bioconjugate chemistry · 2021Article
- Metallofluorocarbon Nanoemulsion for Inflammatory Macrophage Detection via PET and MRI.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
Tissue macrophages play a critical role both in normal physiology and in disease states. However, because of a lack of specific imaging agents, we continue to have a poor understanding of their absolute numbers, flux rates, and functional states in different tissues. Here, we describe a new macrophage specific positron emission tomography imaging agent, labeled with zirconium-89 ((89)Zr), that was based on a cross-linked, short chain dextran nanoparticle (13 nm). Following systemic administration, the particle demonstrated a vascular half-life of 3.9 h and was found to be located primarily in tissue resident macrophages rather than other white blood cells. Subsequent imaging of the probe using a xenograft mouse model of cancer allowed for quantitation of tumor-associated macrophage numbers, which are of major interest in emerging molecular targeting strategies. It is likely that the material described, which allows the visualization of macrophage biology in vivo, will likewise be useful for a multitude of human applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.